Innovative Diagnostic Platform C2N Diagnostics offers a groundbreaking blood test, PrecivityAD, that predicts brain amyloid plaque presence, positioning it as a valuable tool for healthcare providers involved in early Alzheimer’s detection and brain health monitoring. This opens sales opportunities for clinics and hospitals seeking advanced diagnostic solutions for neurological conditions.

Global Regulatory Approvals The company’s PrecivityAD test has received the CE Mark in Europe and a Breakthrough Device Designation from the FDA, indicating strong regulatory validation. These certifications facilitate expansion into international markets and suggest potential sales growth through healthcare systems seeking approved and innovative diagnostic tools.

Strategic Partnerships C2N Diagnostics has established partnerships with leading healthcare providers and organizations across Australia and Brazil to integrate its blood-based diagnostic tests into regional dementia care. Leveraging these collaborations can generate new revenue streams and accelerate market penetration in diverse healthcare settings.

Recent Product Launches The introduction of PrecivityAD2 for patients over 60 demonstrates a commitment to expanding access and capabilities in Alzheimer’s testing. This product evolution presents sales opportunities to clinics and specialty centers focused on age-related neurodegenerative disease management.

Market Positioning With competitors ranging from gene-based diagnostics to genomic health firms, C2N’s focus on blood-based, cost-effective, and accessible tests positions it competitively for healthcare organizations prioritizing early detection and non-invasive diagnostic solutions, offering strong opportunities for targeted outreach and sales expansion.